Introduction to PLA and Duolink Session 1
[[ session.user.profile.firstName ]]
Add profile photo
Change profile photo
[[ session.user.profile.firstName ]]
Add profile photo
Change profile photo
Browse communities
Research and Development
Share this content
Introduction to PLA and Duolink Session 1
Visualization of protein-protein interactions at endogenous levels of expression is a powerful advancement in Life Science. Duolink(R) is a versatile tool for detection, quantification and localization of cytoplasmic signaling events.
PLA(R) provides the ability to see and quantitate protein posttranslational modifications, define complex interactions, illuminate complex protein clusters or amplify low abundant single events.
Watch later
Presentation preview:
Add a photo
[[ session.user.profile.displayName ]]
[[ session.user.profile.jobTitle ]]
[[ session.panyName ]]
[[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
[[ card.displayName ]]
[[ card.jobTitle ]]
[[ panyName ]]
[[ userProfileTemplateHelper.getLocation(card) ]]
Hide me from other attendees
Channel profile
Jeff Gordon, Director of OEM Sales, Cell Marque Corporation
Childhood cancer and pediatric cancer are general terms used to describe a wide range of neoplasms found in children and teenagers. Occurring in approximately 1 in 300 people under the age of 20, compared to 1 in 6 adults, pediatric cancers are more rare than adult cancers. Because less is known about pediatric cancers, diagnosis can be quite challenging for pathologists.
This presentation covers the basic science, as well as facts and statistics about pediatric cancer. We will discuss how the utility of immunohistochemical testing along with the application of novel antibodies can contribute to accurate diagnosis and survival rates of pediatric cancer patients.
Jeff Gordon, Director OEM Sales - Cell Marque Corporation, Rocklin CA
Skin cancer is by far the most prevalent cancer. Each year, approximately 3.4 million people in the US alone are diagnosed with some form of skin cancer.
Skin cancer can be highly treatable if it is detected and classified early, and this detection and classification is often aided by immunohistochemistry.
This presentation covers many of the basic science, facts, and statistics of skin cancer, as well as the utility of immunohistochemical testing with markers such as S-100, SOX-10, Ber-Ep4, and HHV-8 in the accurate diagnosis and survival rates of skin cancer. Continuing education credits for attending this webinar will be offered through the National Society of Histotechnology
Dr. Lily Chan, Cambridge Enterprise
A scientific overview of the portfolio of cell lines University of Cambridge has deposited at ECACC with a focus on the KARPAS 299 and KARPAS 422 the HeLa M and CHO cell lines. We will also provide an overview of the process of partnering with ECACC and Sigma-Aldrich for the storage and distribution of cell lines for research purposes. Topics include: The scientific applicatio The types of companies and instit Advantages of partnering with culture experts and spec Our experience of working with ECACC and Sigma-Aldrich.
Dr. Lily Chan, Cambridge Enterprise
A scientific overview of the portfolio of cell lines University of Cambridge has deposited at ECACC with a focus on the KARPAS 299 and KARPAS 422 the HeLa M and CHO cell lines. We will also provide an overview of the process of partnering with ECACC and Sigma-Aldrich for the storage and distribution of cell lines for research purposes. Topics include: The scientific applicatio The types of companies and instit Advantages of partnering with culture experts and spec Our experience of working with ECACC and Sigma-Aldrich.
Matthias Nold, Product Manager- Merck
Part 3 of a
3-part presentation series about food analysis focused on sample preparation and including information about Reference Material
Uwe Wagner, Marketing Manager - Merck
Part 2 of a
3-part presentation series about food analysis focused on sample preparation and including information about Reference Material
Jennifer Claus, M.S.
Webinar recording for sample preparation on Food Analysis.
Jeff Gordon, Cell Marque- Rocklin, CA
Colorectal cancer is the third most commonly diagnosed cancer in men and women, and is the second leading over all cause of cancer deaths in the United States. Each year, the CDC reports that approximately 135,000 people are diagnosed with colorectal cancer, and over 50,000 succumb each year to the illness.
The National Cancer Institute cites a decline in the mortality rate of colorectal cancer due to advanced screening and early diagnosis.
Immunohistochemistry has served as the catalyst for these advancements in colorectal cancer diagnosis.
This presentation covers many of the basic science, facts, and statistics of colorectal cancer, as well as the utility of immunohistochemical testing with markers such as cadherin?17, CDX?2, SATB2, and the mismatch repair proteins in the accurate diagnosis and survival rates of colorectal cancer.
Jeremy Lehmann- CRISPR Product Specialist, Functional Genomics, MilliporeSigma
CRISPR Cas9 nucleases have revolutionized the field of genome editing enabling unprecedented efficiency of gene targeting in a vast array of cell types and organisms. Even with such powerful technology at hand, researchers who are new to the field may find genome modification to be challenging and time-consuming. As CRISPR becomes a focus of the molecular biology research community, MilliporeSigma seeks to share the best approaches learned and methods applied in our years of genome editing experience. Today’s presentation will focus on practical applications of CRISPR for pristine genome editing to achieve knockout as well as specific sequence changes to include donor-mediated snps, reporter-tags and conditional knockouts. Special attention will be paid to design considerations for the donor constructs necessary to achieve specific sequence changes. Finally, the frontiers of CRISPR technology, including synthetic crRNA to fast-track genome editing experiments, whole genome screening and targeted gene activation will be explored.
Jamie Brown - Supelco R&D Scientist , Lee Marotta - PerkinElmer Senior Field Application Scientist
The new EPA METHOD 325 for sampling Volatile Organic Compounds from Fugitive and Area Sources was promulgated in September of 2015. The petroleum refineries have 2 years to comply with the new ruling. Benzene emissions are the focus of the new ruling, but other VOC’s can be monitored using the same sampling tube. The air samples are collected using thermal desorption tubes that are deployed along fenceline of the property and remain deployed for 14 days. The samples are collected passively, without the using of an air sampling pump. After sampling the diffusive endcap is replaced with a metal storage cap and sent to a laboratory where they’re analyzed by thermal desorption gas chromatography. This is the first of a two series presentation that focuses on the analysis side of the workflow. It provides users the steps required to comply with the new EPA fence line regulations and what is needed to optimize the method for high sample throughput. Refineries and testing laboratories will benefit by gaining valuable information on the optimum techniques to perform this method and what it takes to comply. An introduction to the theory and operation of thermal desorption will also be included.
Dr. Zhen (Calvin) Zhang, Scientist, Project Management, GENEWIZ
Gene synthesis has become a quick and cost-effective way to build your DNA construct for a variety of applications - from protein engineering to bio-based circuit and pathway design. This webinar, presented by Sigma-Aldrich and GENEWIZ will explain the process of gene synthesis, how it compares to traditional cloning techniques, and review some key applications researchers are addressing with synthetic DNA.
Dr. Zhen (Calvin) Zhang, Scientist, Project Management, GENEWIZ
Gene synthesis has become a quick and cost-effective way to build your DNA construct for a variety of applications - from protein engineering to bio-based circuit and pathway design. This webinar, presented by Sigma-Aldrich and GENEWIZ will explain the process of gene synthesis, how it compares to traditional cloning techniques, and review some key applications researchers are addressing with synthetic DNA.
Dr. Kaisa Ukkonen Head of Protein Expression Technologies, BioSilta & Dr. Antti Vasala,R & D Director, BioSilta
EnPresso, a proprietary growth system from BioSilta Ltd, applies slow enzymatic glucose release to control the growth and protein synthesis rate in bacteria and yeasts. This high-cell-density growth system can be used in any shaken cultivation device at various scales. In this webinar, Dr. Kaisa Ukkonen and Dr. Antti Vasala will review the basic requirements for successful high-cell-density cultivations and discuss common reasons for failures in E. coli-based protein production, the focus being on the cultivation conditions. In particular, prerequisites for successful scale-up will be presented. The webinar also features examples on the use of EnPresso demonstrating the time and cost savings enabled by this powerful growth system, and presents an interesting alternative protein expression protocol: IPTG-based autoinduction.
Dr. Lyn Jones, Head of Rare Diseases Chemistry. Chemical Biology Pfizer
Sulfonyl fluorides are privileged protein-reactive functional groups due to their context-specific reactivity with a broad range of amino acid residues (tyrosine, serine, lysine, threonine, cysteine and histidine). As a result, they are ideally suited to a myriad of applications in chemical biology and drug discovery. To highlight the growing utility of sulfonyl fluoride chemical probes, examples will be provided from the literature and work in which Dr. Jones has been involved.
Prof. Vincenzo Palermo, Functional Organic Materials National Research Council, Rome, Italy
Using 2-dimensional nanosheets in a 3-dimensional world:
At the beginning of its exciting life, graphene was mostly a game for physicists. Then, chemists have learned how to “play” with this unique material by enhancing its processability and versatility. Today it is possible, using covalent or supramolecular chemistry, to tailor graphene into a wide variety of forms ranging from simple, soluble sheets to hierarchical architectures where 2-dimensional (2D) graphene sheets are assembled into three-dimensional (3D) composite materials or foams for applications in electronics, mechanics, energy storage or catalysis.
After graphene, the exfoliation of a wide range of layered materials (BN, MoS2, MoSe2, WS2 etc.) has been demonstrated, featuring complementary conductive, semiconductive and insulating properties, opening the way to produce new composite, 2D meta-materials.
More recently, polymerization of small molecules through directional 2D crystallization or cross-linking of self-assembled monolayers was used to obtain self-standing, robust nanosheets featuring a huge variety of chemical structures.
Using these different approaches there is practically no limit to the number of possible 2D structures inspired to graphene that shall be created.
Bill Zuercher- Principal Investigator (UNC Eshelman School of Pharmacy) , Heather King - Senior Scientist (MBD INC)
Chemical probes are powerful reagents with increasing impacts on biomedical research. However, probes of poor quality or that are used incorrectly generate misleading results. To help address these shortcomings, we are building a community-driven online resource to improve quality and convey current best practice.
In this presentation, we will highlight some selected examples of promising, high quality chemical probes and probes of lesser value. We will discuss the prevalence of using lesser quality probes and the costs. We will then detail our plans to develop the Chemical Probes Portal, a web-based resource annotated by the chemical biology community that allows users to reference the most appropriate chemical probe (or probes) for a given protein target. The Portal will be an online community of scientists, reviewers, editors.
Dr. Gregory D. Davis R&D Manager, Molecular Biotechnology Sigma-Aldrich Biotechnology, St. Louis, Missouri
This 30 minute webinar will describe the design and application of pooled CRISPR libraries.
A Sigma-Aldrich technology expert will discuss unique features of Sigma CRISPR pooled libraries with special attention to CRISPR design and cell culture needs.
Jeff Gordon, Director of Sales and Marketing, Cell Marque Corporation A Sigma-Aldrich company
Breast cancer is the most commonly diagnosed cancer in women, and is the second leading cause of death in women. Each year, over 220,000 women (as well as over 2000 men) are diagnosed with breast cancer, and over 40,000 succumb each year to the illness.
With constant advancement of treatment options, the importance of accurate diagnosis and detection of breast cancer becomes more and more relevant to the survival of the patient.
Immunohistochemistry has served as the catalyst for these advancements in breast cancer diagnosis.
This presentation covers many of the basic science, facts, and statistics of breast cancer, as well as the utility of immunohistochemical testing with markers such as e-cadherin, p120 catenin, mammaglobin, and GATA3 in the accurate diagnosis and survival rates of breast cancer.
Prof. Rainer J Chair of Macromolecular Chemistry, School of S Technische Universit?t Dresden, Dresden, Germany
Poly(2-oxazoline) (POx) is a very promising candidate for use in polymer therapeutics. Amphiphilic POx triblock copolymers can be used as high capacity drug delivery systems for hydrophobic drugs, like paclitaxel, and exhibit synergistic effects for the delivery of multiple chemotherapeutics. In this talk, Professor Jordan will highlight the unparalleled high drug-loading capacities of POx systems, the polymer structural variability, and outline the consequences of the drug loading on the drug delivery system morphology.
Amanda Capes-Davis, Chair Person - International Cell Line Authentication Committee (ICLAC)
Cell culture underpins research throughout the life sciences. Continuous cell lines have been used as culture models for many cell types, and assembled into panels for drug discovery and development. However, problems like cross-contamination are quite common and can render some cell lines unsuitable as research models. Authentic cells are typically overgrown by the contaminant over several passages to give a misidentified or false cell line.
Misidentified cell lines can be detected through authentication testing. Short tandem repeat (STR) profiling was subsequently introduced as an international reference method, and a consensus standard for human cell line authentication published by the American National Standards Institute (ANSI). International agreement has allowed all laboratories to compare their cell line stocks, resulting in a new wave of misidentified cell lines being discovered.
Funding bodies and journals are moving to set requirements for reporting of preclinical research. A good understanding of cell line provenance is also essential.
The Sigma-Aldrich Scientific Seminar channel features scientific presentations from key specialists in analytical chemistry, biology, chemistry and life sciences on the practical and technical aspects of new developments and innovations, to help advance your research.
Upcoming webinars (1)
Recorded webinars (104)
Subscribers (12,248)
You can now save presentations to a watch later list and revisit them at your convenience. Click on your profile menu to find your watch later list.
Already have a BrightTALK account?
Cell culture media is required for successful and reproducible research but the catalog is full of acronyms and various formulation tables. Classical mammalian cell culture media formulations are very diverse both in terms of the number available and the concentration of constituents. Additionally, each medium was designed for specific cell types and culturing conditions.
This webinar will cover:
oThe composition, characteristics, environmental factors, and additional supplements required to create optimal conditions for growth and productivity.
oDetermining the right formulation for your application.
oSerum usage and helpful tips for optimizing your culture conditions.
Speaker Bio:
Brian Posey is a Product Development Manager for cell culture media at Corning Life Sciences. Brian has over 10 years experience in cell biology and industrial scale cGMP manufacturing of both liquid and powder cell culture media. Since joining Corning in 2012, Brian has led numerous innovative technology projects for the media business ranging from customer technology transfer for production scale-up to developing new serum-free media for industrial and stem cell lines.
Dell's Chief Medical Officer, Dr. Nick van Terhayden on the Future-Ready Display at DW'15
Before Dr. Nick hovers away on his &Back to the Future& inspired hover board after previewing the Future-Ready innovations on display at the Dell Services booth at Dell World 2015.
As part of a wider digitization initiative, Meander Medical Centre wanted to involve nurses in the development of an app that would help them deliver better patient care. The IT team and nursing staff worked with Dell Digital Business Services to design an app that would be used on the Dell Venue 11 Pro tablet, integrating with the hospital’s electronic medical record system.
Learn more as Dr. Scott Rader, Stratasys, and Dr. Vicknes Waran, Centre for Biomedical and Technology Integration (CBMTI) in Malaysia, discuss how 3D printing can reduce cost, improve care or increase speed at every step in the medical device value chain. This results in increased profitability, technology adoption and market responsiveness. Stratasys solutions shape clinical outcomes and corporate profit.
This webinar will take a look at the Scopus APIs and how you can integrate Scopus content and data into your own websites and applications.
New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades.
The impact will go beyond community pharmacies as other stakeholders also feel the pressure.
UK pharmacies already support more inhabitants per pharmacy than other major E how will this funding change impact how patients are cared for in the community?
How will pharmacy suppliers, such as consumer health companies, operate in the increasingly cost constrained and competitive environment?
Working with our partner, IMS Health, we present an interactive webinar to share market insight on the potential impact and a live discussion with critical stakeholders of this change.
Hear directly from key stakeholders about their thoughts of how the changes will play out, and what this means for you in your sector.
Key topics:
- Digital maturity of pharma
- Hot trends in multichannel marketing
- Evolution of digital budgets
- Key barriers
Join us to hear award-winning author Professor Wilfred Ngwa talk through his latest book Emerging Models for Global Health in Radiation Oncology. Highlighting the emerging models for global radiation oncology, this webinar is essential viewing for researchers, students, health professionals and anyone interested in the global oncology community.
The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world.
Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the crown of UKPLC - being heard in Westminster - and Brussels?
In order to better understand the potential impact of Brexit on both pharma and healthcare in the UK, we are working with specialist IMS Health to bring a unique debate in which a hand-picked panel of experts will discuss and analyse:
The impact of Brexit on UK Healthcare
The ramification of Brexit for pharma in the UK
What does the Brexit scenario mean for global pharma?
Linking the clinical benefit of a product to a real-world benefit that markets care about, insurers will pay for and that will improve patients’ lives is critical for pipeline assets to succeed.
On July 13 Cello Health, in association with PMGroup, will host a free webinar on the value of early asset development and commercialisation.
It will follow the asset development journey, defining value from both a financial and clinical perspective, and look at the variables with which companies must contend in order to optimize a product’s prospects.
Embed in website or blog
Copy and paste this embed code to your website or blog:
Your colleagues' emails:
Successfully added emails: 0
Remove all
Your message:
I thought this webinar was interesting and I wanted to share it with you.
Title: Introduction to PLA and Duolink Session 1
Presented by: Dr. Ola S?derberg, Uppsala University and Tom Juehne, Sigma-Aldrich
Your email has been sent.
Invite more colleagues}